Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure

Data from the Phase III CONTACT-03 study showed the combination of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) fell short of its primary endpoint of progression-free survival in renal cell carcinoma (RCC).